Viking Global Investors LP cut its stake in aTyr Pharma Inc (NASDAQ:LIFE) by 22.1% during the 4th quarter, according to its most recent Form 13F filing with the SEC. The fund owned 1,384,300 shares of the biotechnology company’s stock after selling 393,484 shares during the period. Viking Global Investors LP owned approximately 4.65% of aTyr Pharma worth $4,845,000 as of its most recent SEC filing.
Other institutional investors and hedge funds also recently added to or reduced their stakes in the company. Deutsche Bank AG acquired a new position in aTyr Pharma in the fourth quarter worth $199,000. Dimensional Fund Advisors LP grew its stake in aTyr Pharma by 44.1% during the 3rd quarter. Dimensional Fund Advisors LP now owns 83,848 shares of the biotechnology company’s stock valued at $423,000 after acquiring an additional 25,676 shares in the last quarter. Victory Capital Management Inc. purchased a new position in aTyr Pharma during the 3rd quarter valued at about $455,000. Renaissance Technologies LLC grew its stake in aTyr Pharma by 143.2% during the 4th quarter. Renaissance Technologies LLC now owns 279,400 shares of the biotechnology company’s stock valued at $978,000 after acquiring an additional 164,500 shares in the last quarter. Finally, Artal Group S.A. purchased a new position in aTyr Pharma during the 3rd quarter valued at about $1,263,000. 52.62% of the stock is currently owned by institutional investors and hedge funds.
LIFE has been the topic of several research analyst reports. Zacks Investment Research raised aTyr Pharma from a “hold” rating to a “buy” rating and set a $4.25 target price on the stock in a research note on Saturday, November 18th. ValuEngine lowered aTyr Pharma from a “sell” rating to a “strong sell” rating in a report on Friday, December 1st. Finally, JPMorgan Chase & Co. lowered aTyr Pharma from a “neutral” rating to an “underweight” rating in a report on Wednesday, February 14th. Two investment analysts have rated the stock with a sell rating, two have issued a hold rating and two have given a buy rating to the stock. The company has an average rating of “Hold” and a consensus target price of $4.56.
ILLEGAL ACTIVITY WARNING: “aTyr Pharma Inc (LIFE) Shares Sold by Viking Global Investors LP” was originally reported by American Banking News and is the sole property of of American Banking News. If you are accessing this piece of content on another website, it was illegally copied and republished in violation of United States & international copyright and trademark legislation. The original version of this piece of content can be read at https://www.americanbankingnews.com/2018/03/12/atyr-pharma-inc-life-shares-sold-by-viking-global-investors-lp.html.
aTyr Pharma Company Profile
aTyr Pharma, Inc is a clinical-stage biotherapeutics company. The Company is engaged in the discovery and clinical development of medicines for patients suffering from severe, rare diseases using its Physiocrine biology, a discovered set of physiological modulators. The Company focuses on the development of Physiocrine-based therapeutics for the treatment of rare diseases, including facioscapulohumeral muscular dystrophy (FSHD) and limb-girdle muscular dystrophy (LGMD) 2B.
Receive News & Ratings for aTyr Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for aTyr Pharma and related companies with MarketBeat.com's FREE daily email newsletter.